| Identification | More | [Name]
Lercanidipine hydrochloride | [CAS]
132866-11-6 | [Synonyms]
75
CLAP
mE10
c-E10
CIPER
BCL10
CarMen
LerzaM
Zandip
Lercan
Zanicor
Corifeo
Renovia
Vasodip
Lercadip
Lercapin
Lercaton
LerkaMen
Cardiovasc
BCL-10 human
Lercaridipine
LERCANIDIPINE HCL
B-cell CLL/lymphoma 10
B-cell lymphoma/leukemia 10
LERCANIDIPINE HYDROCHLORIDE
LERCANIDIPINEHYDROCHLORIDE(FORR&DONLY)
Lercanidipine hydrochloride heMihydrate
CARD-containing molecule enhancing NF-κ-B
Lercanidipine hemihydrate hydrochloride
1,4-dihydro-2,6-diMethyl-4-(3-nitrophenyl)-3,5-
1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylicAcid2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimeth
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride
O3-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylic Acid 2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimethylethyl Methyl Ester Hydrochloride
3-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-diMethyl-4-(3-nitrophenyl)-,3-[2-[(3,3-diphenylpropyl)MethylaMino]-1,1-diMethylethyl] 5-Methyl ester,hydrochloride (1:1)
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-[2-[3,3-diphenylpropyl(methyl)amino]-1,1-dimethyl-ethyl] ester O5-methyl ester hydrochloride | [EINECS(EC#)]
603-682-3 | [Molecular Formula]
C36H42ClN3O6 | [MDL Number]
MFCD07773089 | [Molecular Weight]
648.19 | [MOL File]
132866-11-6.mol |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
R25:Toxic if swallowed. | [Safety Statements ]
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
UN 2811 | [WGK Germany ]
3 | [HS Code ]
2933.39.4100 | [Toxicity]
LD50 in mice (mg/kg): 83 i.p.; 657 orally (Nardi) |
| Hazard Information | Back Directory | [Chemical Properties]
Pale-Yellow Powder | [Uses]
A dihydropyridine calcium channel blocker. Antihypertensive. | [Uses]
long-acting dihydropyridine calcium channel blocker, antihypertensive | [Definition]
ChEBI:Lercanidipine hydrochloride is a diarylmethane. | [Brand name]
Cardiovasc (Recor dati, Italy); Carmen (Recordati, Italy); Corifeo (Recordati,
Italy); Lercadip (Recordati, Italy); Lercan (Recordati,
Italy); Lercapin (Recordati, Italy); Lercaton (Recordati,
Italy); Lerkamen (Recordati, Italy); Lerzam (Recordati,
Italy); Renovia (Recordati, Italy); Vasodip (Recordati,
Italy); Zandip (Recordati, Italy); Zanicor (Recordati, Italy). | [Biological Activity]
L-type Ca 2+ channel blocker that displays higher vascular selectivity than Felodipine (4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester ). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive. | [Biochem/physiol Actions]
Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine. | [Clinical Use]
#N/A | [Drug interactions]
Potentially hazardous interactions with other drugs
Aminophylline and theophylline: possibly increased
aminophylline and theophylline concentration.
Anaesthetics: enhanced hypotensive effect.
Antibacterials: metabolism possibly inhibited by
clarithromycin, erythromycin and telithromycin -
avoid with erythromycin.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antiepileptics: effect reduced by carbamazepine,
barbiturates, phenytoin and primidone.
Antifungals: metabolism possibly inhibited by
itraconazole and ketoconazole - avoid; negative
inotropic effect possibly increased with itraconazole.
Antihypertensives: enhanced hypotensive effect,
increased risk of first dose hypotensive effect of postsynaptic alpha-blockers.
Antivirals: concentration increased by ritonavir -
avoid.
Cardiac glycosides: digoxin concentration increased.
Ciclosporin: concentration of both drugs may be
increased - avoid.
Grapefruit juice: concentration increased - avoid | [storage]
Store at -20°C |
|
|